Beginning in 2003, news stories charged that hundreds of National Institutes of Health scientists were engaged in ethically dubious practices, including consulting for or holding stock in companies whose products might benefit from NIH support. After internal and congressional probes of these potential conflicts of interest, NIH Director Elias A. Zerhouni announced on Feb. 1 "drastic" ethics reforms.
From now on, no one at NIH may accept even unpaid side work with any organization that might have a financial interest in any research or other activity going on at, or supported by, the agency. Furthermore, NIH employees in key positions and members of their immediate families will be forced to sell stock holdings in biomedical firms. Other employees may hold no more than $15,000 in such stocks.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.